ReviewBritish journal of clinical pharmacology2013
Drug-conjugated antibodies for the treatment of cancer.
Review in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 144 citations in OpenAlex.
- Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.International journal of breast cancer · 2026Article
- Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.Cancer cell international · 2025Review
- Corneal Findings in Patients Treated with Belantamab Mafodotin: A Prospective Case Series Focusing on Corneal Nerves.Ophthalmology and therapy · 2025Article
- Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.Cancer chemotherapy and pharmacology · 2024Review
- Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.Pharmaceutics · 2022Review
- Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application.Drug delivery · 2021Article
- Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.Pharmaceutics · 2021Review
- Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.American journal of ophthalmology case reports · 2021Article
- Immunotherapy in endometrial cancer: rationale, practice and perspectives.Biomarker research · 2021Review
- Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem cell research & therapy · 2021Review
- Recent advances of antibody drug conjugates for clinical applications.Acta pharmaceutica Sinica. B · 2020Review
- Characterization of T-DM1-resistant breast cancer cells.Pharmacology research & perspectives · 2020Article
- Immunotherapy in Multiple Myeloma.Cells · 2020Review
- Antibody-drug conjugates: smart weapons against cancer.Archives of medical science : AMS · 2020Article
- Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.Cancer medicine · 2019Article
- In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis.Blood advances · 2019Article
- Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.Investigational new drugs · 2018Article
- Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.Targeted oncology · 2018Review
- Site-Specific Antibody Conjugation for ADC and Beyond.Biomedicines · 2017Review
- The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.Neoplasia (New York, N.Y.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite considerable effort, application of monoclonal antibody technology has had only modest success in improving treatment outcomes in patients with solid tumours. Enhancing the cancer cell-killing activity of antibodies through conjugation to highly potent cytotoxic 'payloads' to create antibody-drug conjuates (ADCs) offers a strategy for developing anti-cancer drugs of great promise. Early ADCs exhibited side-effect profiles similar to those of 'classical' chemotherapeutic agents and their performance in clinical trials in cancer patients was generally poor. However, the recent clinical development of ADCs that have highly potent tubulin-acting agents as their payloads have profoundly changed the outlook for ADC technology. Twenty-five such ADCs are in clinical development and one, brentuximab vedotin, was approved by the FDA in August, 2011, for the treatment of patients with Hodgkin's lymphoma and patients with anaplastic large cell lymphoma, based on a high rate of durable responses in single arm phase II clinical trials. More recently, a second ADC, trastuzumab emtansine, has shown excellent anti-tumour activity with the presentation of results of a 991-patient randomized phase III trial in patients with HER2-positive metastatic breast cancer. Treatment with this ADC (single agent) resulted in a significantly improved progression-free survival of 9.6 months compared with 6.4 months for lapatinib plus capecitabine in the comparator arm and significantly prolonged overall survival. Besides demonstrating excellent efficacy, these ADCs were remarkably well tolerated. Thus these, and other ADCs in development, promise to achieve the long sought goal of ADC technology, that is, of having compounds with high anti-tumour activity at doses where adverse effects are generally mild.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.